• Other

S16 Ep42: Variability and Innovation in Small Cell Lung Cancer Care: With Ticiana Leal, MD

pharminent March 31, 2026

• Commercial

Novartis, Takeda Add Hundreds to Workforce Chopping Block

pharminent March 31, 2026

• M&A / Deals

Biogen swoops on Apellis with $5.6bn offer

pharminent March 31, 2026

• M&A / Deals

Eli Lilly makes $7.8bn takeover play for Centessa

pharminent March 31, 2026

• M&A / Deals

Merck strikes deal with antibody discovery startup

pharminent March 31, 2026

• Market Access

UCB brings first therapy for rare disease TK2d to EU

pharminent March 31, 2026

• Other

Drug Channels News Roundup, March 2026: Cigna’s 340B Workaround, Merck’s ARPA Surprise, Walgreens’ Automation Bet, Why Rebates Hurt Patients, and a DCI Team Photo

pharminent March 31, 2026

• Other

Biotech IPOs stayed at slow pace, but grew larger in the first quarter of 2026

pharminent March 31, 2026

• Regulatory

AZ considers filings for long-acting Strensiq follow-up

pharminent March 31, 2026

• Regulatory

S16 Ep40: FDA Approval Insights: Zongertinib for HER2 TKD-Mutated NSCLC: With Julia Rotow, MD; and Martin Dietrich, MD, PhD

pharminent March 30, 2026

• M&A / Deals

Blackstone closes $6.3B fund for life sciences investing

pharminent March 30, 2026

• Clinical Data

Kardigan Blood Pressure Drug Proves Hypothesis Despite Split Phase 2 Readout

pharminent March 30, 2026

• Regulatory

Biogen Bounces Back With FDA Nod for High-Dose Spinal Muscular Atrophy Drug

pharminent March 30, 2026

• Clinical Data

Biogen’s Lupus Drug Reduces Disease Activity, Further Deresking I&I Pipeline

pharminent March 30, 2026

• Other

One in four diabetics has undiagnosed heart failure; study

pharminent March 30, 2026

• Market Access

The Top Pharmacy Benefit Managers of 2025: Market Share and Key Industry Developments

pharminent March 30, 2026

• Regulatory

Amgen’s BiTE for lung cancer backed for EU approval

pharminent March 30, 2026

• Other

Trustworthy AI in clinical oversight

pharminent March 30, 2026

• M&A / Deals

Otsuka grows in neuroplastogens with $1.225bn Transcend buy

pharminent March 29, 2026

• M&A / Deals

Lilly puts up to $2.75bn into Insilico alliance

pharminent March 29, 2026

• Other

S16 Ep38: Live Tumor Board: Precision Pathways Transforming Patient Care in Advanced NSCLC

pharminent March 27, 2026

• Regulatory

Accord, Intas, and Bio-Thera File Four IPRs Against Janssen Golimumab Patents

pharminent March 27, 2026

• M&A / Deals

Otsuka picks up PTSD drug with $700M Transcend buy

pharminent March 27, 2026

• Clinical Data

AstraZeneca lung drug gets ‘surprise’ win in COPD trials

pharminent March 27, 2026

• M&A / Deals

Novartis targets Xolair successor in buyout of startup Excellergy

pharminent March 27, 2026

• Commercial

The Rare Journey Needs a Special Pharmacy Partner

pharminent March 27, 2026

• M&A / Deals

Merck’s deal for Terns sparks debate over a possible biotech bidding war

pharminent March 26, 2026

• Regulatory

FDA clears Denali drug in ‘clear step’ for rare disease biotechs

pharminent March 26, 2026

• Clinical Data

Wave crashes on obesity drug update; Kodiak’s reboot pays dividends

pharminent March 26, 2026

• Clinical Data

Maze tumbles despite positive data for kidney disease drug

pharminent March 25, 2026

• Clinical Data

Beam posts positive data on base editing treatment for AATD

pharminent March 25, 2026

• Clinical Data

Sarepta sees early success with RNAi drugs from Arrowhead

pharminent March 25, 2026

• M&A / Deals

Merck to buy Terns in $6.7B bet on a ‘differentiated’ leukemia drug

pharminent March 25, 2026

• Clinical Data

Karyopharm myeloma drug yields mixed data in myelofibrosis trial

pharminent March 24, 2026

• M&A / Deals

Gilead, with Ouro deal, wagers $1.7B on bispecifics for autoimmune diseases

pharminent March 24, 2026

• M&A / Deals

RA Capital targets China with latest SPAC deal

pharminent March 24, 2026

• M&A / Deals

Immutrin raises $87M to advance drug for progressive heart disease

pharminent March 24, 2026

• Regulatory

FDA seeks feedback on voucher program; Study data lift ‘overhang’ on Insmed shares

pharminent March 24, 2026

• Other

NOW AVAILABLE: The 2026 Economic Report on U.S. Pharmacies and Pharmacy Benefit Managers

pharminent March 24, 2026

• Business
• Pipeline

How former Acorda CEO Ron Cohen landed at a Parkinson’s cell therapy startup

pharminent March 24, 2026